Using Cheminformatics in Drug Discovery. 2016

Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
Simulations Plus, Inc., Lancaster, CA, USA. mlawless@simulations-plus.com.

This chapter illustrates how cheminformatics can be applied to designing novel compounds that are active at the primary target and have good predicted ADMET properties. Examples of various cheminformatics techniques are illustrated in the process of designing inhibitors that inhibit both cyclooxygenase isoforms but are more potent toward COX-2. The first step in the process is to create a knowledge database of cyclooxygenase inhibitors in the public domain. This data was analyzed to find activity cliffs - small structural changes that result in drastic changes in potency. Additional cyclooxygenase potency and selectivity trends were obtained using matched molecular pair analysis. QSAR models were then developed to predict cyclooxygenase potency and selectivity. Next, computational algorithms were used to generate novel scaffolds starting from known cyclooxygenase inhibitors. Nine virtual libraries containing 240 compounds each were constructed. Predictions from the cyclooxygenase QSAR models were used to eliminate molecules with undesirable potency or selectivity. Additionally, the compounds were screened in silico for undesirable ADMET properties, e.g., low solubility, permeability, metabolic stability, or high toxicity, using a liability scoring system known as ADMET Riskā„¢. Eight synthetic candidates were identified from this process after incorporating knowledge gained from activity cliff analysis. Four of the compounds were synthesized and tested to measure their COX-1 and COX-2 IC(50) values as well as several ADME properties. The best compound, SLP0020, had a COX-1 IC(50) of 770 nM and COX-2 IC(50) of 130 nM.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D048088 Informatics The field of information science concerned with the analysis and dissemination of data through the application of computers.
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug
D020650 Combinatorial Chemistry Techniques A technology, in which sets of reactions for solution or solid-phase synthesis, is used to create molecular libraries for analysis of compounds on a large scale. Chemistry Techniques, Combinatorial,Techniques, Combinatorial Chemistry,Chemistry Technic, Combinatorial,Chemistry Technics, Combinatorial,Chemistry Technique, Combinatorial,Combinatorial Chemistry Technic,Combinatorial Chemistry Technics,Combinatorial Chemistry Technique,Technic, Combinatorial Chemistry,Technics, Combinatorial Chemistry,Technique, Combinatorial Chemistry
D021281 Quantitative Structure-Activity Relationship A quantitative prediction of the biological, ecotoxicological or pharmaceutical activity of a molecule. It is based upon structure and activity information gathered from a series of similar compounds. Structure Activity Relationship, Quantitative,3D-QSAR,QSAR,QSPR Modeling,Quantitative Structure Property Relationship,3D QSAR,3D-QSARs,Modeling, QSPR,Quantitative Structure Activity Relationship,Quantitative Structure-Activity Relationships,Relationship, Quantitative Structure-Activity,Relationships, Quantitative Structure-Activity,Structure-Activity Relationship, Quantitative,Structure-Activity Relationships, Quantitative

Related Publications

Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
September 2002, Drug discovery today,
Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
March 2018, ChemMedChem,
Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
December 2020, Molecular informatics,
Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
September 2018, Molecular informatics,
Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
January 2018, Methods in molecular biology (Clifton, N.J.),
Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
January 2013, Current topics in medicinal chemistry,
Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
May 2001, Current opinion in drug discovery & development,
Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
January 2018, Methods in molecular biology (Clifton, N.J.),
Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
December 2020, Drug discovery today,
Michael S Lawless, and Marvin Waldman, and Robert Fraczkiewicz, and Robert D Clark
January 2021, Frontiers in chemistry,
Copied contents to your clipboard!